Abstract
Introduction
All animal experiments were approved by the Animal Research Committee of the were recorded as previously described 20 . All mice were euthanized on day 42.
168

Statistical Analysis
169
Data are all presented as mean±SEM. Student t-test was used for comparison between 170 two groups while two-way ANOVA was used for comparisons between multiple groups.
Docetaxel-mediated tumor cell injury induces the expression of M2 cytokines
174
To study the impact of docetaxel in prostate cancer, we first examined the dose 175 response of this chemotherapeutic agent on several prostate cancer cell lines ( Figure 1A ).
176
We found that PCa cells exhibit a wide range of sensitivity to docetaxel, with C4-2 (IC50 177 = 2nM) and CWR22Rv1 (IC50 = 5nM) being the most sensitive, PC-3 (IC50 = 30nM) as CRPC.
279
In this study, we investigated whether TAMs, an important component of the chain (Munder, et al. 2006; Rodriguez, et al. 2004 ). Interestingly, a recent study by
309
Gordon et al (Gordon, et al. 2017) further implicated that PD-1 expressing TAMs are 310 inhibiting tumor immunity, which might further empower the efficacy of the PD-1 or PD-311 L1 checkpoint blockade.
312
In our collective experience of studying TAM's influences in cancer therapy, we 
55
Expression of CSF-1 and IL-10 and Ki-67 in response to paclitaxel treatment was shown.
56
(B) The impacts of paclitaxel treatment at IC50 on PCa cells in the presence of 57 macrophages (RAW cells) were shown for Myc-CaP, CWR22Rv1, PC3 (50nM) and C4-58 Figure 2 . CSF-1R inhibitor PLX3397 abrogated the increased recruitment of macrophages induced by docetaxel treatment in vitro. Conditioned media of CWR22Rv1 (A) and C4-2 (B) prostate cancer cells treated with docetaxel was able to recruit more RAW macrophages migrating across a transwell porous membrane than media from untreated cells. The addition of 2µM CSF-1Ri PLX3397 to the docetaxel treated conditioned media abrogated the increased macrophage recruitment induced by both cell lines. In a second set of similar study, the increase in RAW macrophages migration by CWR22Rv1 (C) and C4-2 (D) conditioned media was inhibited by 1µM GW2580, a selective CSF-1R kinase inhibitor. (*: p<0.05, **: p<0.01) 188x224mm (150 x 150 DPI) Figure 3 . The addition of PLX3397 to docetaxel improves therapeutic efficacy in CRPC by reducing the protumorigenic influences of TAMs. The therapeutic effects of combining CSF-1Ri PLX3397 with docetaxel were evaluated in subcutaneous Myc-CaP tumors established in FVB male mice. Seven days after tumor cell implantation, all mice received surgical castration and randomly assigned to 4 treatment groups: (i) control,
(ii) PLX3397, (iii) docetaxel or (iv) docetaxel+PLX3397. Flow cytometric analyses of CD11b+CSF1R+ TAM population in the tumor were shown as individual representative flow plots (A) and for each treatment cohort (B). Longitudinal tumor volume (C) and final tumor size (D, E) were shown for the 4 treatment groups. Intraprostatic CWR22Rv1 tumors were established with firefly luciferase marked cells, and longitudinal tumor growth were monitored by in vivo BLI (F, G). Tumor growth suppression was more effective in the docetaxel + PLX3397 group compared to the docetaxel only group (H, I) as assessed by terminal tumor volume. Likewise the PLX3397 containing treatment group was significantly reduced in the proportion of CD11b+ CSF1R+ TAM as analyzed by flow cytometry (J), and immunohistochemistry with F4/80 macrophages (K) and the tissue remodeling marker MMP-9 (L). Gene expression profiling by qRT-PCR
